The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

Olverembatinib targets oncogenic Src-family kinases (Lck, Fyn, and YES1), which are essential for T-cell differentiation, survival, and activation. Combined with lisaftoclax, Ascentage Pharma ...